Dear Author,

Please check these proofs carefully. It is the responsibility of the corresponding author to check against the original manuscript and approve or amend these proofs. A second proof is not normally provided. Informa Healthcare cannot be held responsible for uncorrected errors, even if introduced during the composition process. The journal reserves the right to charge for excessive author alterations, or for changes requested after the proofing stage has concluded.

A version of your manuscript showing the language edits as tracked changes is appended to the typeset proofs. This document is provided for reference purposes only. Please mark all your corrections to the typeset pages at the front of the PDF. Corrections marked to the tracked changes section will not be incorporated in the published document.

The following queries have arisen during the editing of your manuscript and are marked in the margins of the proofs. Unless advised otherwise, submit all corrections using the CATS online correction form. Once you have added all your corrections, please ensure you press the “Submit All Corrections” button.

AQ1 Please review the table of contributors below and confirm that the first and last names are structured correctly and that the authors are listed in the correct order of contribution.

<table>
<thead>
<tr>
<th>Contrib No.</th>
<th>Given Name(s)</th>
<th>Surname</th>
<th>Suffix</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Mohammad</td>
<td>Mohammad</td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td>Ihab M.</td>
<td>Al-Masri</td>
<td></td>
</tr>
<tr>
<td>3.</td>
<td>Ala</td>
<td>Issa</td>
<td></td>
</tr>
<tr>
<td>4.</td>
<td>Mohamed A.S.</td>
<td>Al-Ghussein</td>
<td></td>
</tr>
<tr>
<td>5.</td>
<td>Mohammad</td>
<td>Fararjeh</td>
<td></td>
</tr>
<tr>
<td>6.</td>
<td>Hatim</td>
<td>Alkatib</td>
<td></td>
</tr>
<tr>
<td>7.</td>
<td>Mutasem O.</td>
<td>Taha</td>
<td></td>
</tr>
<tr>
<td>8.</td>
<td>Yasser</td>
<td>Bustanji</td>
<td></td>
</tr>
</tbody>
</table>

AQ2 Please check and approve the running head or provide an alternative.

AQ3 Please carefully check the authors names and affiliations.

AQ4 Please provide city and state of Upstate Biotechnology.

AQ5 Please provide city and state of Biosource.

AQ6 Please provide city and state of Sigma.

AQ7 Please provide city and state of Accelrys Inc.

AQ8 Please provide city and state of Cambridge Soft Corp.

AQ9 Please provide city and state of Omega.
**Famotidine inhibits glycogen synthase kinase-3β: An investigation by docking simulation and experimental validation**

Mohammad Mohammad, Ihab M. Al-Masri, Ala Issa, Mohamed A.S. Al-Ghussein, Mohammad Fararjeh, Hatim Alkatib, Mutasem O. Taha, and Yasser Bustanji

1Faculty of Pharmacy, University of Jordan, Amman 11942, Jordan, 2Faculty of Pharmacy, Al-Azhar University, Gaza, Gaza Strip, and 3Faculty of Allied Health Sciences, The Hashemite University, Zarqa, Jordan

**Abstract**

Famotidine was investigated as an inhibitor of glycogen synthase kinase-3β (GSK-3β) in an attempt to explain the molecular mechanism of its hypoglycemic side effects. The investigation included simulated docking experiments, *in vitro* enzyme inhibition assay, glycogen sparing studies using animal models and single dose oral glucose tolerance test (OGTT). Docking studies showed how famotidine is optimally fit within the binding pocket of GSK-3β via numerous attractive interactions with some specific amino acids. Experimentally, famotidine could inhibit GSK-3β (IC$_{50} = 1.44 \mu M$) and increased significantly liver glycogen spares in fasting animal models. Moreover, a single oral dose of famotidine was shown to decrease the glycemic response curve after 75 g OGTT.

**Keywords:** Famotidine, glycogen synthase kinase, docking simulation, H2-receptor antagonist

**Introduction**

Famotidine is a specific, long-acting H$_2$-receptor antagonist which competes the binding of histamine to their receptors in the parietal cells. Famotidine decreases basal, nocturnal, pentagastrin and food-stimulated gastric acid production$^1$. Famotidine is indicated for the management of peptic ulcer, esophageal refluxes, and the treatment of pathological hypersecretory conditions, like Zollinger–Ellison syndrome$^2$. Generally, famotidine is well tolerated in patients with various disorders like cardiovascular, renal and hepatic dysfunctions, moreover it is considered to have excellent safety profiles$^3$. Nevertheless, it is well known that H$_2$-receptor inhibitors affect hormone metabolism$^4$; however, their effect on glucose metabolism is not well investigated. In fact several discrepancies are reported concerning the effects produced by these compounds on glycemic level$^5$$^7$. In addition, most studies have investigated the effect of cimetidine and ranitidine and only few data are available for famotidine. In 2003, a study, carried out to investigate the effect of famotidine on some hematobiochemical parameters in mice, has revealed a glucose-lowering effect for famotidine$^8$.

Recently, an extensive molecular modeling experiments, employing different molecular modeling techniques as pharmacophore modeling, QSAR predictions and docking investigations, were conducted to find out novel glycogen synthase kinase-3β (GSK-3β) inhibitors$^9$. Cimetidine (I, Figure 1) was found to have a potent anti-GSK-3β bioactivity *in vitro* and illustrated a hypoglycemic activity and glycogen reservation capability *in vivo*. These findings were consistent with several previous studies which reported a significant cimetidine-induced hypoglycemia$^{10}$. No studies were conducted to investigate the direct effect of famotidine on GSK-3β activity. The central role of GSK-3β in glucose metabolism and the structural similarities between cimetidine (I) and famotidine (II) (Figure 1) have encouraged us to investigate GSK-3β-inhibitory activity of famotidine as well as its effect on glycogen levels in animals and blood glucose level. To investigate if famotidine can...
Figure 1. Molecular structure of both Cimitidine (I) and Famotidine (II).

Figure 2. Molecular structure of co-crystallized structure AR-A014418.

**Materials and methods**

The 3D coordinates GSK-3β were recovered from the Protein Data Bank (PDB code: 1Q5K, resolution = 1.94 Å). The DS visualizer 2.0 templates for protein residues (Accelrys discovery studio (DS) visualizer 2.0, Accelrys Inc., San Diego, California, USA) was used to extract the co-crystallized ligand and to add hydrogen atoms to the protein. Famotidine chemi- cal structure was sketched in ChemDraw Ultra (10.0), and saved in MDL molfile format (CS ChemDraw Ultra, Inc.) was used to explore the conformational space of famotidine.

Famotidine was docked into the binding site of GSK-3β utilizing docking capabilities of FRED software (FRED version 2.2.5, OpenEye Scientific Software (www. eyesopen.com))13. This docking software considers a multiconformer database of multiple ligands, a target protein structure, a box defining the active site of the protein based on the co-crystallized ligand and other optional parameters as input.

FRED’s docking process is used to thoroughly score all possible poses of each ligand in the active site15. The exhaustive search is based on rigid rotations and translations of each conformer. The best docking situations utilized were those succeeded to retrieve the pose of the co-crystallized ligand (AR-A014418, Figure 2). For more details about the docking experiment and docking parameters employed see references14,15.

**In vitro GSK-3β enzyme inhibitory assay**

GSK-3β was dissolved in a buffer solution (pH 7.2) containing the following: 40 mM HEPES; 5 mM MgCl2; 5 mM EDTA; 100 μM ATP and 50 μg/ml heparin to get a concentration of 10 pg/ml. Subsequently, 50 μl aliquots of the enzymatic solution were transferred into 0.5 ml vials. Thereafter, appropriate volumes of famotidine stock solution were pipetted to the enzymatic solution to give final concentration of 0.1, 1, and 10 μM and the volumes were then completed up to 75 μl. Famotidine was incubated with the enzyme over 30 min at room temperature, then a proper volume of Tau solution (25 μl of 2000 pg/ml HEPES) was added to get a final concentration of 500 pg/ml. This mixture was incubated over 1 h at room temperature.

Tau phosphorylation was detected as previously described by Bustanj et al.14 A standard GSK-3β inhibitor (TDZD-8) was applied as positive control16 in this experiment.

**In vivo evaluation**

**Preparation of famotidine doses**

The effect of famotidine on liver glycogen content of fasting Balb/c mice was investigated. Famotidine suspension was suspended in 0.5% carboxy methylcellulose phosphate buffer saline (pH 7.2). For control animals, the vehicle without famotidine was employed. Three escalating doses of famotidine were used: 1.1, 2.2 and 4.4 mg/kg. These doses correspond to human dose, double the human dose and four times human dose, respectively. All famotidine doses were injected i.p. (ca. 0.20mL) to yield the desired dosage after normalization to mouse weight (ca. 20 g).

**Determination of liver glycogen**

All animal experiments comply with the Guide for the Care and Use of Laboratory Animals published by the US
National Institutes of Health. 10-week old male Balb/c mice of average weight of 20 g, obtained from Jordan University animal house, Jordan, were used for the investigations. The animals were randomly selected and fed ad libitum with standard feed and water. Animals were housed in the same conditions and separated randomly in four-mouse groups (5 animals each). The first group was injected i.p. with the vehicle as negative control. The other three groups were injected with the three escalating doses of famotidine. These doses are (i) human dose (1.1 mg/Kg) (ii) double the normalized human dose, and (iii) four times the normalized human dose. All doses were normalized to mouse weight (ca. 20 g).

Animals were fasted for at least four hours before the doses administration. Three hours after the famotidine administration, the animals were sacrificed by cervical dislocation and their livers were removed immediately for glycogen determination. Liver glycogen content was determined quantitatively using anthrone reagent method. For further procedure details see references.[14,15]

Oral glucose tolerance test (OGTT)
The study was placebo-controlled crossover study. Six healthy human volunteers (28-40 years old) were fasted for at least 10 h before the starting point of experiments in which they received single oral doses of famotidine 80 mg or placebo, separated by at least 7-d washout interval. Thirty minutes after the administration, the participants were perorally administered with 225 ml containing 75 g glucose (consumed within 5 min). Plasma was obtained by centrifugation (3000 rpm) and plasma glucose determination were measured before and 30, 60, and 120 min after the administration with glucose by the hexokinase method. The study was conducted in accordance with the guidelines in the Declaration of Helsinki. Written informed consent was obtained after the purpose, nature and potential risks had been explained to the subjects. All subjects were within 10% of ideal body weight, and none had undergone abdominal surgery or were taking any medications. All the subjects enrolled in this study were ethnic Caucasian. Subjects who are smoking and/or alcoholic were excluded.

Data are presented as means ± SEM. Statistical comparisons were performed using Student’s t-test. In all cases, p < 0.05 is considered statistically significant.

Results and discussion
Efforts to investigate the inhibitory effect of famotidine on GSK-3β were started by using in-silico docking technique to investigate its possibility of binding within GSK-3β binding pocket. The docking simulations were conducted using FRED docking engine. The binding pocket was defined from the crystallographic structure of AR-A014418[11], which is a known GSK-3β ligand with high affinity (Figure 2).

The molecular modeling study of famotidine-GSK-3β binding has shown that famotidine can be successfully docked within the binding pocket of GSK-3β making several significant interactions with key hot spots within the GSK-3β binding pocket. Figure 3 shows the solvent accessible surface as well as the key residues of GSK-3β binding site with the co-crystallized inhibitor AR-A014418 (Figure 3A) and the highest ranking docked pose of famotidine (Figure 3B). However, to validate our docking scoring procedure, we employed the same docking conditions to dock AR-A014418 into the binding pocket of GSK-3β. Docking simulations created close models to the crystallographic structure (RMSD = 0.84 Å, Figure 4), which supported the docking results of famotidine into GSK-3β binding site, as shown in Figure 3B, and supports our conclusions regarding famotidine/GSK-3β binding.

Comparison of the highest ranking docked pose of famotidine (Figure 3B) with the co-crystallized ligand within the binding site of GSK-3β (Figure 3A) illustrates similarities in their binding profile. Both have strong hydrogen bond interactions with the key amino acids PRO-136 and VAL-135 and potential hydrophobic interactions with the key amino acids Val135 and Pro136, respectively. The docked model of famotidine illustrates that the molecule is well accommodated within the binding site of GSK-3β, with the key interactions occurring at the corresponding residues.

Figure 3. (A) Detailed view of the co-crystallized structure (AR-A014418) and the corresponding interacting amino-acids within the binding site of GSK-3β. (B) Detailed view of the docked famotidine structure and the corresponding interacting amino-acid moieties within the binding site of GSK-3β.
effects of famotidine on animal's liver glycogen levels and OGTT.

The proposed inhibitory action of famotidine was experimentally validated against recombinant GSK-3β. The in vitro inhibition activity was expressed as the concentration of famotidine that inhibits the enzymatic activity by 50% (IC_{50}) when compared to the uninhibited enzymatic reaction performed under the same conditions. The inhibitory effects of three escalating concentrations; (0.1, 1, and 10 µM) of famotidine on GSK-3β activity was performed. Results have shown that these concentrations could inhibit GSK-3β activity in a dose dependent manner showing 29.4, 35.5, 71.2% inhibition, respectively. Linear regression of these results revealed ($R^2 = 0.918$) an estimated IC_{50} value of 1.44 µM TDZD-8, a standard GSK-3β inhibitor showed an IC_{50} value of 1.5 µM that is comparable to the published value.

Moreover, famotidine significantly increased liver glycogen reserves in fasting Balb/c mice in a dose-dependent manner. Figure 5 shows the responses of liver glycogen reserves to i.p. administered famotidine at doses 1.1, 2.2, 4.4 mg/kg normalized to mice weight. It is obvious in this figure that there is a significant elevation of liver glycogen (fourfold increase) with the use of the highest dose of famotidine (4.4 mg/kg).

Finally, we have also investigated whether oral glucose tolerance is improved in healthy volunteers by famotidine. Blood glucose levels were measured before and 30, 60, and 120 min after famotidine administration. Serum glucose levels were observed to be significantly decreased 30 min after oral glucose load following famotidine administration (113.0 ± 14 mg/dl compared to the control value of 139.0 ± 17 mg/dl; $p < 0.05$). Similarly, blood glucose level significantly decreased 60 min after glucose load from 167.0 ± 32 to 132.0 ± 21 mg/dl ($p < 0.05$). At 120 min, serum glucose levels decreased to less than 120 mg/dl (93.0 ± 14 mg/dl compared to the control value of 126.0 ± 21 mg/dl; $p < 0.05$). Average area under the serum glucose-time curve also was decreased significantly (13415 compared to the control value of 17020; $p < 0.05$), as shown in Figure 6. This is the first report indicating that famotidine improves the glycemic curve in OGTT.

Glycogen metabolism is tightly regulated metabolic process and is under the control of various metabolic signals. GSK-3β plays crucial role in the regulation of glycogen synthesis through phosphorylation and thus inhibition of the activity of glycogen synthase which is a key metabolic enzyme in the glycogen synthesis pathway. Consequently, inhibitors of GSK-3β could improve glucose disposal via increasing the rate of glycogen synthesis in the liver and skeletal muscles. In our study, the significant increase in liver glycogen reserves caused by famotidine may be attributed, at least partially, to its inhibitory action of GSK-3β, a hypothesis that was supported by the initial docking studies.
Fig. 6. Glycemic response during a 75 g OGTT (n = 6) in healthy humans with (▲) or without (■) famotidine (80 mg p.o.). Asterisks denote a significant difference compared to the control values. Data are expressed as geometric mean ± SEM.

Conclusion

In summary, our studies provide evidence that famotidine could inhibit GSK-3β in vitro. Moreover, we provide evidence showing that famotidine promotes glucose metabolism in healthy humans. A single oral dose of famotidine was shown to lessen the glycemic response curve after 75 g OGTT. These effects were paralleled by the enhancement in liver glycogen synthesis in vivo.

Acknowledgements

This project was sponsored by the Deanship of Scientific Research at the University of Jordan. The authors wish to thank the Deanship of Scientific Research. The authors would like to thank also the OpenEye Scientific Software Corporation for providing free license of FRED software.

Declaration of interest

The authors report no declarations of interest.

References

Famotidine inhibits glycogen synthase kinase-3β: An investigation by docking simulation and experimental validation

Mohammad Mohammad, Ihab M. Al-Masri, Ala Issa, Mohamed A.S. Al-Ghussein, Mohammad Fararjeh, Hatim Alkatib, Mutasem O. Taha, and Yasser Bustanji

Faculty of Pharmacy, University of Jordan, Amman 11942, Jordan, Faculty of Pharmacy, Al-Azhar University, Gaza, Gaza Strip, and Faculty of Allied Health Sciences, The Hashemite University, Zarqa, Jordan

Address for Correspondence: Mohammad Mohammad, Faculty of Pharmacy, University of Jordan, Amman 11942, Jordan. Tel.: +962 6 5355000x23316; fax: +962 6 5339649. E-mail: mkmohammad@ju.edu.jo

Abstract

Famotidine was investigated as an inhibitor of glycogen synthase kinase-3β (GSK-3β) in an attempt to explain the molecular mechanism of its hypoglycemic side effects. The investigation included simulated docking experiments, in vitro enzyme inhibition assay, glycogen sparing studies using animal models and single dose oral glucose tolerance test (OGTT). Docking studies showed how famotidine is optimally fit within the binding pocket.
of GSK-3β via numerous attractive interactions with some specific amino acids. Experimentally, famotidine could inhibit GSK-3β ($IC_{50} = 1.44 \mu M$) and increased significantly liver glycogen spares in fasting animal models. Moreover, a single oral dose of famotidine was shown to decrease the glycemic response curve after 75 g OGTT

**Keywords:** Famotidine, glycogen synthase kinase, docking simulation, H2-receptor antagonist

**Introduction**

Famotidine is a specific, long-acting H$_2$-receptor antagonist which competes the binding of histamine to their receptors in the parietal cells. Famotidine decreases basal, nocturnal, pentagastrin and food-stimulated gastric acid production\cite{1}. Famotidine is indicated for the management of peptic ulcer, esophageal refluxes, and the treatment of pathological hypersecretory conditions, like Zollinger–Ellison syndrome\cite{2}. Generally, famotidine is well tolerated in patients with various disorders like cardiovascular, renal and hepatic dysfunctions, moreover it is considered to have excellent safety profiles\cite{3}. Nevertheless, it is well known that H$_2$-receptor inhibitors affect hormone metabolism\cite{4}, however, their effect on glucose metabolism is not well investigated. In fact several discrepancies are reported concerning the effects produced by these compounds on glycemic level\cite{5}. In addition, most studies have investigated the effect of cimetidine and ranitidine and only few data are available for famotidine. In 2003, a study, carried out to investigate the effect of famotidine on some hematobiochemical parameters in mice, has revealed a glucose-lowering effect for famotidine\cite{8}.

Recently, an extensive molecular modeling experiments, employing different molecular modeling techniques as pharmacophore modeling, QSAR predictions and docking investigations, were conducted to find out novel glycogen synthase kinase-3β (GSK-3β)
Cimetidine (I, Figure 1) was found to have a potent anti-GSK-3β bioactivity in vitro and illustrated a hypoglycemic activity and glycogen reservation capability in vivo. These findings were consistent with several previous studies which reported a significant cimetidine-induced hypoglycemia. No studies were conducted to investigate the direct effect of famotidine on GSK-3β activity. The central role of GSK-3β in glucose metabolism and the structural similarities between cimetidine (I) and famotidine (II) (Figure 1) have encouraged us to investigate GSK-3β-inhibitory activity of famotidine as well as its effect on glycogen levels in animals and blood glucose level. To investigate if famotidine can bind to GSK-3β active site, an initial molecular docking was performed as a preliminary in-silico screening test.

**Materials and methods**

**Materials**

Chemicals used in these experiments were of analytical grade and purchased from commercial suppliers: Recombinant GSK-3β (from Upstate Biotechnology); Tau [pS396] phosphoELISA kit (Biosource); Assay buffer components (HEPES; MgCl2 and EDTA, Biosource); ATP (Sigma); heparin (Sandoz GmbH, Austria); Anthrone (Sigma); Thiourea (Sigma).

**Molecular modeling**

The 3D coordinates of GSK-3β were recovered from the Protein Data Bank (PDB code: 1Q5K, resolution = 1.94 Å). The DS visualizer 2.0 templates for protein residues (Accelrys discovery studio (DS) visualizer 2.0, Accelrys Inc.) was used to extract the co-crystallized ligand and to add hydrogen atoms to the protein. Famotidine chemical structure was sketched in ChemDraw Ultra (10.0), and
saved in MDL molfile format (CS ChemDraw Ultra 10.0, Cambridge Soft Corp. (http://www.cambridgesoft.Com), [AU: Please provide city and state of Cambridge Soft Corp.]). OMEGA software (Omega, version 2.3.2, OpenEye Scientific Software (www.eyesopen.com), [AU: Please provide city and state of Omega]) was used to explore the conformational space of famotidine.

Famotidine was docked into the binding site of GSK-3β utilizing docking capabilities of FRED software (FRED version 2.2.5, OpenEye Scientific Software (www.eyesopen.com)). This docking software considers a multiconformer database of multiple ligands, a target protein structure, a box defining the active site of the protein based on the co-crystallized ligand and other optional parameters as input.

FRED’s docking process is used to thoroughly score all possible poses of each ligand in the active site. The exhaustive search is based on rigid rotations and translations of each conformer. The best docking situations utilized were those succeeded to retrieve the pose of the co-crystallized ligand (AR-A014418, Figure 2). For more details about the docking experiment and docking parameters employed see references.

In vitro GSK-3β enzyme inhibitory assay

GSK-3β was dissolved in a buffer solution (pH 7.2) containing the following: 40 mM HEPES; 5 mM MgCl2; 5 mM EDTA; 100 μM ATP and 50 μg/ml heparin to get a concentration of 10 pg/ml. Subsequently, 50 μl aliquots of the enzymatic solution were transferred into 0.5 ml vials. Thereafter, appropriate volumes of famotidine stock solution were pipetted to the enzymatic solution to give final concentration of 0.1, 1, and 10 μM and the volumes were then completed up to 75 μl. Famotidine was incubated with the enzyme over 30 min at room temperature, then a proper volume of Tau solution (25 μl of 2000 pg/ml in HEPES) was added to get a final concentration of 500 pg/ml. This mixture was incubated over 1 h at room temperature.
Tau phosphorylation was detected as previously described by Bustanji et al. A standard GSK-3β inhibitor (TDZD-8) was applied as positive control in this experiment.

**In vivo evaluation**

**Preparation of famotidine doses.**

The effect of famotidine on liver glycogen content of fasting Balb/c mice was investigated. Famotidine suspension was suspended in 0.5% carboxy methylcellulose phosphate buffer saline (pH 7.2). For control animals, the vehicle without famotidine was employed. Three escalating doses of famotidine were used: 1.1, 2.2 and 4.4 mg/kg. These doses correspond to human dose, double the human dose and four times human dose, respectively. All famotidine doses were injected i.p. (ca. 0.20mL) to yield the desired dosage after normalization to mouse weight (ca. 20 g).

**Determination of liver glycogen**

All animal experiments comply with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health. 10-week old male Balb/c mice of average weight of 20 g, obtained from Jordan University animal house, Jordan, were used for the investigations. The animals were randomly selected and fed *ad libitum* with standard feed and water. Animals were housed in the same conditions and separated randomly in four-mouse groups (5 animals each). The first group was injected i.p. with the vehicle as negative control. The other three groups were injected with the three escalating doses of famotidine. These doses are (i) human dose (1.1mg/Kg) (ii) double the normalized human dose, and (iii) four times the normalized human dose. All doses were normalized to mouse weight (ca. 20 g).

Animals were fasted for at least four hours before the doses administration. Three hours after the famotidine administration, the animals were sacrificed by cervical dislocation and their livers were removed immediately for glycogen determination. Liver glycogen
content was determined quantitatively using anthrone reagent method. For further procedure details see references.

**Oral glucose tolerance test (OGTT)**

The study was placebo-controlled crossover study. Six healthy human volunteers (28–40 years old) were fasted for at least 10 h before the starting point of experiments in which they received single oral doses of famotidine 80 mg or placebo, separated by at least a 7-d washout interval. Thirty minutes after the administration, the participants were perorally administered with 225 ml containing 75 g glucose (consumed within 5 min). Plasma was obtained by centrifugation (3000 rpm) and plasma glucose determination were measured before and 30, 60, and 120 min after the administration with glucose by the hexokinase method. The study was conducted in accordance with the guidelines in the Declaration of Helsinki. Written informed consent was obtained after the purpose, nature and potential risks had been explained to the subjects. All subjects were within 10% of ideal body weight, and none had undergone abdominal surgery or were taking any medications. All the subjects enrolled in this study were ethnic Caucasian. Subjects who are smoking and/or alcoholic were excluded.

Data are presented as means ± SEM. Statistical comparisons were performed using Student’s *t*-test. In all cases, *p* < 0.05 is considered statistically significant.

**Results and discussion**

Efforts to investigate the inhibitory effect of famotidine on GSK-3β were started by using in-silico docking technique to investigate its possibility of binding within GSK-3β binding pocket. The docking simulations were conducted using FRED docking engine. The binding pocket was defined from the crystallographic structure of AR-A014418, which is a known GSK-3β ligand with high affinity (Figure 2).
The molecular modeling study of famotidine-GSK-3β binding has shown that famotidine can be successfully docked within the binding pocket of GSK-3β making several significant interactions with key hot spots within the GSK-3β binding pocket. Figure 3 shows the solvent accessible surface as well as the key residues of GSK-3β binding site with the co-crystallized inhibitor AR-A014418 (Figure 3A) and the highest ranking docked pose of famotidine (Figure 3B). However, to validate our docking-scoring procedure, we employed the same docking conditions to dock AR-A014418 into the binding pocket of GSK-3β. Docking simulations created close models to the crystallographic structure (RMSD = 0.84 Å, Figure 4), which supported the docking results of famotidine into GSK-3β binding site, as shown in Figure 3B and supports our conclusions regarding famotidine/GSK-3β binding.

Comparison of the highest ranking docked pose of famotidine (Figure 3B) with the co-crystallized ligand within the binding site of GSK-3β (Figure 3A) illustrates similarities in their binding profile. Both have strong hydrogen bond interactions with the key amino acids PRO-136 and VAL-135 and potential hydrophobic interaction with LEU-188. However, famotidine showed more several important interactions which might contribute to its high GSK-3β binding affinity and inhibitory activity. The guanidine group of famotidine interacts with the sulfahydryl moiety of CYS-199 and carboxyl group of ASP-200 through hydrogen bonding (2.2 Å) and electrostatic interactions (3.2 Å), respectively. Moreover, the terminal NH$_2$ group makes a strong hydrogen bond with the OH of the TYR-143 (2.2 Å), while the sulfonyl group is hydrogen bonded to LYS-60 (2.5 Å). Furthermore, the sulfur atom in the thioether flexible chain in famotidine has a potential hydrophobic interaction with ILE-62. Overall, these attractive interactions cooperate in stabilizing the proposed complex. This preliminary docking simulation finding has encouraged us to further evaluate the inhibitory actions of famotidine in vitro and to investigate the effects of famotidine on animal’s liver glycogen levels and OGTT.
The proposed inhibitory action of famotidine was experimentally validated against recombinant GSK-3β. The *in vitro* inhibitory activity was expressed as the concentration of famotidine that inhibits the enzymatic activity by 50% (IC$_{50}$) when is compared to the uninhibited enzymatic reaction performed under the same conditions$^{[4]}$. The inhibitory effects of three escalating concentrations; (0.1, 1, and 10 µM) of famotidine on GSK-3β activity was performed. Results have shown that these concentrations could inhibit GSK-3β activity in a dose dependent manner showing 29.4, 35.5, 71.2% inhibition, respectively. Linear regression of these results revealed ($R^2 = 0.918$) an estimated IC$_{50}$ value of 1.44 µM TDZD-8, a standard GSK-3β inhibitor showed an IC$_{50}$ value of 1.5 µM that is comparable to the published value$^{[6]}$.

Moreover, famotidine significantly increased liver glycogen reserves in fasting Balb/c mice in a dose-dependent manner. Figure 5 shows the responses of liver glycogen reserves to i.p. administered famotidine at doses 1.1, 2.2, 4.4 mg/kg normalized to mice weight. It is obvious in this figure that there is a significant elevation of liver glycogen (fourfold increase) with the use of the highest dose of famotidine (4.4 mg/kg).

Finally, we have also investigated whether oral glucose tolerance is improved in healthy volunteers by famotidine. Blood glucose levels were measured before and 30, 60, and 120 min after famotidine administration. Serum glucose levels were observed to be significantly decreased 30 min after oral glucose load following famotidine administration (113.0 ± 14 mg/dl compared to the control value of 139.0 ± 17 mg/dl; $p < 0.05$). Similarly, blood glucose level significantly decreased 60 min after glucose load from 167.0 ± 32 to 132.0 ± 21 mg/dl ($p < 0.05$). At 120 min, serum glucose levels decreased to less than 120 mg/dl (93.0 ± 14 mg/dl compared to the control value of 126.0 ± 21 mg/dl; $p < 0.05$). Average area under the serum glucose-time curve also was decreased significantly (13415
compared to the control value of 17020; p < 0.05), as shown in Figure 6. This is the first report indicating that famotidine improves the glycemic curve in OGTT.

Glycogen metabolism is tightly regulated metabolic process and is under the control of various metabolic signals. GSK-3β plays crucial role in the regulation of glycogen synthesis through phosphorylation and thus inhibition of the activity of glycogen synthase which is a key metabolic enzyme in the glycogen synthesis pathway. Consequently, inhibitors of GSK-3β could improve glucose disposal via increasing the rate of glycogen synthesis in the liver and skeletal muscles. In our study, the significant increase in liver glycogen reserves caused by famotidine may be attributed, at least partially, to its inhibitory action of GSK-3β, a hypothesis that was supported by the initial docking studies.

Conclusion

In summary, our studies provide evidence that famotidine could inhibit GSK-3β in vitro. Moreover, we provide evidence showing that famotidine promotes glucose metabolism in healthy humans. A single oral dose of famotidine was shown to lessen the glycemic response curve after 75 g OGTT. These effects were paralleled by the enhancement in liver glycogen synthesis in vivo.

Acknowledgements

This project was sponsored by the Deanship of Scientific Research at the University of Jordan. The authors wish to thank the Deanship of Scientific Research. The authors would like to thank also the OpenEye Scientific Software Corporation for providing free license of FRED software.

Declaration of interest

The authors report no declarations of interest.

References


Figure 1. Molecular structure of both Cimitidine (I) and Famotidine (II).

Figure 2. Molecular structure of co-crystallized structure AR-A014418.

Figure 3. (A) Detailed view of the co-crystallized structure (AR-A014418) and the corresponding interacting amino-acids within the binding site of GSK-3β. (B) Detailed view of the docked famotidine structure and the corresponding interacting amino-acid moieties within the binding site of GSK-3β.

Figure 4. Comparison between the docked conformer/pose of inhibitor AR-A014418 (dark black) as produced by the docking simulation and the crystallographic structure of this inhibitor within GSK-3β (gray, PDB code: 1Q5K).

Figure 5. Liver glycogen reserves in fasting 10-week old male Balb/c mice three hours after i.p. administration of vehicle control, 1.1, 2.2 and 4.4 mg/kg of famotidine normalized to mice weights (20 g). Each result represents the average glycogen level from 5 mice. Error bars indicate the standard deviations of the measurements. (*) p value < 0.05 versus control.

Figure 6. Glycemic response during a 75 g OGTT (n = 6) in healthy humans with (▲) or without (■) famotidine (80 mg p.o.). Asterisks denote a significant difference compared to the control values. Data are expressed as geometric mean ± SEM.